ImmunityBio, Inc. (IBRX)
Automate Your Wheel Strategy on IBRX
With Tiblio's Option Bot, you can configure your own wheel strategy including IBRX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IBRX
- Rev/Share 0.0366
- Book/Share -0.6921
- PB -3.8578
- Debt/Equity -0.0687
- CurrentRatio 2.2185
- ROIC -1.1962
- MktCap 2356595400.0
- FreeCF/Share -0.4418
- PFCF -6.2525
- PE -5.5682
- Debt/Assets 0.1335
- DivYield 0
- ROE 0.6488
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | IBRX | Piper Sandler | Neutral | Overweight | -- | $5 | May 20, 2025 |
| Initiation | IBRX | H.C. Wainwright | -- | Buy | -- | $8 | March 6, 2025 |
| Initiation | IBRX | BTIG Research | -- | Buy | -- | $6 | Jan. 10, 2025 |
News
ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer
Published: June 03, 2025 by: Business Wire
Sentiment: Neutral
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced results presented at ASCO 2025 of the first known treatment for lymphopenia with ANKTIVA and CAR-NK therapy. This data supports that reversal of lymphopenia, a well-established root cause of early mortality in patients with cancer across all tumor types, correlates with significant improved survival. While anemia and neutropenia have long been addressed by agents like Epogen and Neupogen, no therapy has ever.
Read More
ImmunityBio (IBRX) Moves to Buy: Rationale Behind the Upgrade
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
ImmunityBio (IBRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates
Published: May 12, 2025 by: Zacks Investment Research
Sentiment: Negative
ImmunityBio (IBRX) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to loss of $0.20 per share a year ago.
Read More
ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug
Published: May 05, 2025 by: Benzinga
Sentiment: Negative
ImmunityBio, Inc. IBRX on Monday received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for the supplemental biologics license application (sBLA) for use of ANKTIVA plus Bacillus Calmette-Guerin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) for the indication of papillary disease.
Read More
ImmunityBio (IBRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Negative
ImmunityBio (IBRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
ImmunityBio to Host Investor Day
Published: March 26, 2025 by: Business Wire
Sentiment: Neutral
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, invites current and prospective investors to its Investor Day program to be held on Tuesday, April 15, 2025, at 10:00 am PDT. The program will include an in-depth update on the company's business operations and recent R&D advancements. Key timelines for catalysts of product candidates will be presented, along with a discussion of ongoing clinical trials. “ImmunityBio commenced 2025 with.
Read More
ImmunityBio (IBRX) Reports Q4 Loss, Misses Revenue Estimates
Published: March 03, 2025 by: Zacks Investment Research
Sentiment: Negative
ImmunityBio (IBRX) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.19 per share a year ago.
Read More
IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is Investigating ImmunityBio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK , Feb. 27, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against ImmunityBio, Inc. (NASDAQ: IBRX) on behalf of long-term stockholders following a class action complaint that was filed against ImmunityBio on August 29, 2023 with a Class Period from May 23, 2022 to May 10, 2023. Our investigation concerns whether the board of directors of ImmunityBio have breached their fiduciary duties to the company.
Read More
About ImmunityBio, Inc. (IBRX)
- IPO Date 2015-07-28
- Website https://immunitybio.com
- Industry Biotechnology
- CEO Mr. Richard Gerald Adcock
- Employees 671